EyePoint Pharmaceuticals has commercially launched Dexycu in the U.S. for the treatment of postoperative inflammation.
Dexycu (dexamethasone intraocular suspension 9%) is administered at the end of cataract surgery and is the first FDA-approved intraocular steroid for postoperative inflammation.
Its launch will be phased, with the first phase including leading cataract surgery experts.
“There are approximately 4.8 million cataract surgeries a year in the U.S.,” Nancy Lurker, president and CEO of EyePoint, said in a press release. “Dexycu offers a single-dose, sustained-release treatment option conveniently administered at the end of cataract surgery which can eliminate the complicated and burdensome steroid eye drop regimen following surgery.”